Deceptive Advertising! Claims Novo in GLP-1 Lawsuit Fallout
Two pharmaceutical giants are in court over GLP-1 advertising. This tangle could redefine how GLP-1s are marketed and...
Compare top high-yield ETFs by income potential and durability to select funds that optimize retirement cash flow and resilience.
27,330 articlesTwo pharmaceutical giants are in court over GLP-1 advertising. This tangle could redefine how GLP-1s are marketed and...
Comfort Systems USA is set to report Q4 FY2025 after the bell, with shares up about 65% over the past year. Analysts ...
When a prominent fund makes a sizable stake reduction, it often signals more than profit-taking. This article breaks ...
Analysts see strong demand for Nvidia's AI hardware and software ecosystem. This piece breaks down why great news NVI...
A real-world financial wake-up call shows how a missing tarantula collection can expose gaps in protection, insurance...
A major government contract marks a turning point for Palantir. This analysis explains how the DHS deal could reshape...
A dramatic one-day move put Relay Therapeutics in the spotlight. After encouraging Phase 2 results for zovegalisib an...
A fresh look at an internal code snippet raises questions about Anthropic’s plans for Fable 5, potentially tying week...
A high-profile insider move raises questions about strategy and sentiment. This article breaks down the Paychex share...
A notable stake in Magnite signals a contrarian take on the ad tech landscape. This article breaks down the move, wha...
As the AI arms race accelerates, Microsoft leans on Copilot to reverse signals of lost momentum. Early traction and p...
Icon stock crushed Wednesday as the CRO leader posted a stronger quarter than expected. We break down what drove the ...